CLINICAL TRIALS PROFILE FOR JNJ-42165279
✉ Email this page to a colleague
Clinical Trials for JNJ-42165279
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01650597 ↗ | A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants | Completed | Janssen-Cilag International NV | Phase 1 | The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single ascending doses as well as repeated doses of JNJ-42165279 in healthy male participants. |
| NCT01826786 ↗ | The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers | Completed | Janssen Research & Development, LLC | Phase 1 | The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers. |
| NCT01964651 ↗ | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants | Completed | Janssen Research & Development, LLC | Phase 1 | The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy, young and elderly, male and female participants after repeated oral dose administration. |
| NCT02065739 ↗ | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants | Completed | Janssen Pharmaceutica N.V., Belgium | Phase 1 | The purpose of this study is to assess the effects of repeated administration of 200 mg of itraconazole on the single-dose pharmacokinetics of JNJ-42165279 in healthy male participants. |
| NCT02169973 ↗ | A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279 | Completed | Janssen Research & Development, LLC | Phase 1 | The purpose of the study is to measure the uptake, distribution, and clearance of 11C-MK-3168 by Positron Emission Tomography (PET) scan and to model the tissue specific kinetics of 11C-MK-3168 with the appropriate input function in human brain in Part A; to measure blocking of retention of 11C-MK-3168 at the estimated time to maximum plasma concentration after dosing (tmax) following each single oral doses of JNJ-42165279 and model the exposure/enzyme interaction of JNJ-42165279 in Part B; to measure the saturation of enzyme inhibition in the brain at steady state plasma concentrations of JNJ-42165279 (on Day 8) after 7 once-daily doses of JNJ-42165279 by conducting PET studies with 11C-MK-3168 at trough plasma concentrations on Day 2 in Part C. |
| NCT02432703 ↗ | A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Completed | Janssen Research & Development, LLC | Phase 2 | The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for JNJ-42165279
Condition Name
Clinical Trial Locations for JNJ-42165279
Trials by Country
Clinical Trial Progress for JNJ-42165279
Clinical Trial Phase
Clinical Trial Sponsors for JNJ-42165279
Sponsor Name
